332 related articles for article (PubMed ID: 30655151)
41. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
42. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen.
Hézode C; Chevaliez S; Scoazec G; Soulier A; Varaut A; Bouvier-Alias M; Ruiz I; Roudot-Thoraval F; Mallat A; Féray C; Pawlotsky JM
Hepatology; 2016 Jun; 63(6):1809-16. PubMed ID: 26853230
[TBL] [Abstract][Full Text] [Related]
43. Utilizing Clinical Pharmacist Specialist to Manage Hepatitis C Virus Patients on Direct-Acting Antiviral Therapy.
Mikolas LA; Jacques K; Huq M; Krasner C; Mambourg SE
J Pharm Pract; 2019 Dec; 32(6):655-663. PubMed ID: 29783912
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
[TBL] [Abstract][Full Text] [Related]
45. Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual.
Johnson SW; Davis MM; Stever LM; Priest DH
J Clin Pharm Ther; 2016 Dec; 41(6):727-729. PubMed ID: 27670742
[TBL] [Abstract][Full Text] [Related]
46. Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation.
Turgeon MK; Shah SA; Delman AM; Tran BV; Agopian VG; Wedd JP; Magliocca JF; Kim A; Cameron A; Olyaei A; Orloff SL; Anderson MP; Kubal CA; Cannon RM; Locke JE; Simpson MA; Akoad ME; Wongjirad CP; Emamaullee J; Moro A; Aucejo F; Feizpour CA; Vagefi PA; Nguyen MH; Esquivel CO; Dhanireddy K; Subramanian V; Chavarriaga A; Kazimi MM; Anderson MS; Sonnenday CJ; Kim SC; Foley DP; Abdouljoud M; Salgia RJ; Moris D; Sudan DL; Ganesh SR; Humar A; Doyle M; Chapman WC; Maithel SK
Ann Surg; 2021 Oct; 274(4):613-620. PubMed ID: 34506316
[TBL] [Abstract][Full Text] [Related]
47. Improvement in Liver Stiffness in Pediatric Patients with Hepatitis C Virus after Treatment with Direct Acting Antivirals.
Mogahed EA; El-Karaksy H; Abdullatif H; Yasin NA; Nagy A; Alem SA; Eldeen HG; El-Raziky MS
J Pediatr; 2021 Jun; 233():126-131. PubMed ID: 33577805
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence.
Teegen EM; Dürr M; Maurer MM; Eurich F; Vollbort A; Globke B; Bahra M; Blaeker H; Pratschke J; Eurich D
Transpl Infect Dis; 2019 Feb; 21(1):e13020. PubMed ID: 30375710
[TBL] [Abstract][Full Text] [Related]
49. Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.
Elmasry S; Wadhwa S; Bang BR; Cook L; Chopra S; Kanel G; Kim B; Harper T; Feng Z; Jerome KR; Kahn JA; Saito T
Gastroenterology; 2017 Feb; 152(3):550-553.e8. PubMed ID: 27838287
[TBL] [Abstract][Full Text] [Related]
50. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.
Terrault NA; Zeuzem S; Di Bisceglie AM; Lim JK; Pockros PJ; Frazier LM; Kuo A; Lok AS; Shiffman ML; Ben Ari Z; Akushevich L; Vainorius M; Sulkowski MS; Fried MW; Nelson DR;
Gastroenterology; 2016 Dec; 151(6):1131-1140.e5. PubMed ID: 27565882
[TBL] [Abstract][Full Text] [Related]
51. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
[TBL] [Abstract][Full Text] [Related]
52. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
[TBL] [Abstract][Full Text] [Related]
53. Effectiveness of chronic hepatitis C treatment with direct-acting antivirals in the Public Health System in Brazil.
Holzmann I; Tovo CV; Minmé R; Leal MP; Kliemann MP; Ubirajara C; Aquino AA; Araujo B; Almeida PRL
Braz J Infect Dis; 2018; 22(4):317-322. PubMed ID: 30036490
[TBL] [Abstract][Full Text] [Related]
54. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
55. Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients.
Saab S; Greenberg A; Li E; Bau SN; Durazo F; El-Kabany M; Han S; Busuttil RW
Liver Int; 2015 Nov; 35(11):2442-7. PubMed ID: 25913321
[TBL] [Abstract][Full Text] [Related]
56. Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES.
Butt AA; Yan P; Shaikh OS; Chung RT; Sherman KE;
Liver Int; 2016 May; 36(5):651-8. PubMed ID: 26616353
[TBL] [Abstract][Full Text] [Related]
57. Treatment of chronic hepatitis C viral infection with sofosbuvir and daclatasvir in kidney transplant recipients.
Huang H; Tang H; Deng H; Shen J; Zhou Q; Xie W; Wu J; Chen J
Transpl Infect Dis; 2019 Feb; 21(1):e13018. PubMed ID: 30369001
[TBL] [Abstract][Full Text] [Related]
58. Sofosbuvir and daclatasvir plus ribavirin treatment improve liver function parameters and clinical outcomes in Egyptian chronic hepatitis C patients.
Mohamed MS; Hanafy AS; Bassiony MAA; Hussein S
Eur J Gastroenterol Hepatol; 2017 Dec; 29(12):1368-1372. PubMed ID: 28953002
[TBL] [Abstract][Full Text] [Related]
59. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
Kawaoka T; Imamura M; Morio K; Nakamura Y; Tsuge M; Nelson Hayes C; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ohdan H; Chayama K
Clin J Gastroenterol; 2017 Apr; 10(2):179-184. PubMed ID: 28224470
[TBL] [Abstract][Full Text] [Related]
60. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
Mansour M; Hill L; Kerr J
Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
